KR900018136A - 항응집성 펩티드 - Google Patents
항응집성 펩티드 Download PDFInfo
- Publication number
- KR900018136A KR900018136A KR1019890006198A KR890006198A KR900018136A KR 900018136 A KR900018136 A KR 900018136A KR 1019890006198 A KR1019890006198 A KR 1019890006198A KR 890006198 A KR890006198 A KR 890006198A KR 900018136 A KR900018136 A KR 900018136A
- Authority
- KR
- South Korea
- Prior art keywords
- arg
- gly
- asp
- cys
- alk
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 6
- 150000001875 compounds Chemical class 0.000 claims abstract 26
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract 17
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract 16
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 238000000034 method Methods 0.000 claims abstract 6
- 150000001413 amino acids Chemical class 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 239000011347 resin Substances 0.000 claims 7
- 229920005989 resin Polymers 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000003527 fibrinolytic agent Substances 0.000 claims 6
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- SHDMMLFAFLZUEV-UHFFFAOYSA-N n-methyl-1,1-diphenylmethanamine Chemical compound C=1C=CC=CC=1C(NC)C1=CC=CC=C1 SHDMMLFAFLZUEV-UHFFFAOYSA-N 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 3
- 108010023197 Streptokinase Proteins 0.000 claims 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 229960005202 streptokinase Drugs 0.000 claims 2
- 229960005356 urokinase Drugs 0.000 claims 2
- RGTVXXNMOGHRAY-WDSKDSINSA-N Cys-Arg Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RGTVXXNMOGHRAY-WDSKDSINSA-N 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 1
- 230000003480 fibrinolytic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000006798 ring closing metathesis reaction Methods 0.000 claims 1
- 108010073863 saruplase Proteins 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 4시간 후의 응괴용해율(%)을 조직 플라스미노겐 활성화제(tPA)의 농도증가에 따른 함수로서 나타낸 그래프이다.
Claims (23)
- 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염X-(A)m-B-Gly-Asp-(C)n-Y (Ⅰ)상기식에서 A는 Arg, HArg, (Me2)Arg, (Et2)Arg, Ala, Gly, His, Abu 또는 이들의 α-R' 치환된 유도체 또는 Pro 이고; B는 Arg, HArg, (Me2)Arg, (Et2)Arg, 또는 이들의 α-R' 치환된 유도체이며; C는 Tyr, (Alk)Tyr, Phe, (4'w)Phe, HPhe, Phg, trp, His, Ser, (Alk)Ser, Thr, (Alk)Thr, Cys, (Alk)Cys, Pen, (Alk)Pen, ala, Val, Nva, Met, Leu, Ile, Nle 또는 Nal중에서 선택된 D- 또는 L-아미노산이고; W는 할로겐 또는 Alk이며; Y는 NR1R2또는 OR3이고; R1및 R2는 각각 독립적으로 수소, Alk 또는 (CH2)pPh이며; R3는 Alk, (CH2)pPh 또는 B가 HArg, (ME2)Arg 또는 (Et2)Arg 또는 Arg, HArg, (Me2)Arg 또는 (Et2)Arg의 α-R'치환된 유도체일때, H이고; X는 R4R5N이며; R4는 수소 또는 Alk이고; R5는 수소, Alk, HCO, AIKCO, PhCH2또는 Ph(CH2)9CO이며; P'는 Alk 또는 PhCH2이고; q,m및 n은 0 또는 1이며; p는 0,1,2 또는 3이다.
- 제1항에 있어서, C가 Ser, (Me)Ser, Thr, Tyr, Phe, Nal 또는 Val인 화합물.
- 일반식(Ⅱ)의 화합물 또는 이의 약제학적으로 허용되는 염.상기식에서 A'는 Arg, HArg, (Me2)Arg, (Et2)Arg, Alg, Gly, His, Abu, Lys 또는 이들의 α-R'치환된 유도체 또는 Pro중에서 선택된 D- 또는 L-아미노산이고; B'는 Arg, HArg, (Me2)Arg, (Et2)Arg, Lys 또는 이들의 α-R'치환된 유도체중에서 선택된 D- 또는 L-아미노산이며; C'는 Tyr, (Alk)Tyr, Phe, (4'w)Phe,HPhe, Phg, Trp, His, Ser, (Alk)Ser, Thr, (Alk)Thr, (Alk)Cys, (Alk)Pen, Ala, Val, Nva, Met, Leu, He, Nle 또는 Nal 또는 이들의 α-R' 치환된 유도체 중에서 선택된 D- 또는 L-아미노산이고; W는 할로겐 또는 Alk이며; Y는 NR1R2또는 OR3이고; R1및 R2는 각각 독립적으로 수소, Alk 또는 (CH2)pPh이며; R3는 Alk, (CH2)|pPh 또는, B가 HArg, (Me2)Arg 또는 (Et2)Arg 또는 Arg, HArg, (Me2)Arg 또는 (Et2)Arg의 α-R' 치환된 유도체일 때, 수소이고; X는 R4R5N 또는 수소이며; R4는 수소 또는 Alk이고; R5는 수소, Alk, HCO, AlKCO, PhCH2또는 Ph(CH2)9CO이며; R'는 Alk 또는 PhCH2이고; Z1은 Cys, Pen 또는 APmp의 D- 또는 L-이성체이며, Z2은 Cys, Pen 또는 APmp의 D- 또는 L- 이성체이고; q, m및 n은 독립적으로 0또는 1이며; p는 0,1,2 또는 3이다.
- 제3항에 있어서, C'가 Ser, (Me)Ser, Thr, Tyr, Phe 또는 Nal인 화합물.
- 제1항 내지 제4항중 어느 한 항에 있어서, A 또는 A'가 Arg 또는 Gly인 화합물.
- 제1항 내지 제5항중 어느 한 항에 있어서, B 또는 B'가 HArg 또는 Arg 또는 HArg의 α-R' 치환된 유도체이고, m 또는 n이 0인 화합물.
- 제3항에 있어서, m및 n이 모두 0인 화합물.
- 제1항 내지 제7항중 어느 한 항에 있어서, B 또는 B'가 MeArg인 화합물.
- 제1항에 있어서, 다음 구조식의 화합물중 어느 하나의 화합물: Nα-AC-MeArg-Gly-Asp-Ser-NH2; Nα-AC-Arg-Gly-Asp-Ser-NH2; Nα-AC-Arg-Gly-Asp-Tyr-NH|2; Nα-AC-Arg-Gly-Asp-NH2; Nα-AC-Arg-Gly-Asp-D-Ser-NH2; Nα-AC-Arg-Gly-Asp-Val-NH2; Nα-AC-Arg-Gly-Asp-Nal-NH2; Nα-AC-Arg-Arg-Gly-Asp-Phe-NH|2; Nα-AC-Arg-Gly-Asp-NH-CH2-CH2-C6H5; Nα-AC-MeArg-Gly-Asp-Phe-NH|2; NαAC-HArg-Gly-Asp-Ser-NH2; Nα-AC-Arg-Gly-Asp-Ser-NHEt; Nα-MeArg-Gly-Asp-Ser-NH2; Nα-Formyl-MeArg-Gly-Asp-Ser-NH2; 및 Gly-MeArg-Gry-Asp-Ser-NH2.
- 제3항에 있어서, 다음 구조식의 화합물중 어느 하나의 화합물: Nα-Ac-Cyclo(S,S)Cys-MeArg-Gly-Asp-Ser-Cys-NH2; Nα-Ac-Cyclo(S,S)Cys-Arg-Gly-Asp-(D,L)APMP-NH2; Nα-Ac-Cyclo(S,S)Cys-Arg-Gly-Asp-Ser-Cys-NH2; Cyclo(S,S)Mpr-Arg-Gly-Asp-Ser-Cys-NH2; Nα-Ac-Cyclo(S,S)Cys-MeArg-Gly-Asp-Ser-Pen-NH2; Nα-Ac-Cyclo(S,S)Cys-MeArg-Gly-Asp-(Me)Ser-Cys-NH2; Cyclo(S,S)Mpr-MeArg-Gly-Asp-Ser-Cys-NH2; Nα-Ac-Cyclo(S,S)Cys-MeArg-Gly-Asp-Cys-NH2; Cyclo(S,S)Mpr-MeArg-Gly-Asp-Pen-NH2; Nα-AC-Cyclo(S,S)Cys-Arg-Gly-Asp-Pen-NH2; Nα-AC-Cyclo(S,S)Cys-Arg-Gly-Asp-E-Pen-NH2; Nα-Ac-Cyclo(S,S)Cys-Lys-Gly-Asp-Pen-NH2; Nα-Ac-Cyclo(S,S)Cys-HArg-Gly-Asp-Pen-NH2; Nα-Ac-Cyclo(S,S)Cys-MeArg-Gly-Asp-Pen-NH2; Nα-Ac-Cyclo(S,S)Cys-Arg-Gly-Asp-PenNHEt; Nα-Ac-Cyclo(S,S)Cys-MeArg-Gly-Asp-Ser-Cys-NH2; Nα-Ac-Cyclo(S,S)Cys-MeArg-Gly-Asp-Tyr-Cys-NH2; Nα-Ac-Cyclo(S,S)Pen-MeArg-Gly-Asp-Pen-NH2; Nα-Ac-Cyclo(S,S)Pen-Arg-Gly-Asp-Cys-NH2; Nα-Ac-Cyclo(S,S)Cys-D-Arg-Gly-Asp-Ser-Cys-NH2; Nα-Ac-Cyclo(S,S)Cys-Sar-Arg-Gly-Asp-Pen-NH2; Nα-Ac-Cyclo(S,S)Cys-Arg-Gly-Asp-Cys-NH2; Nα-Ac-Cyclo(S,S)Cys-Arg(Et2)-Gly-Asp-Pen-NH2; 및 Nα-Ac-Cyclo(S,S)Cys-D-MeArg-Gly-Asp-Pen-NH2.
- 제9항에 있어서, Nα-Ac-MeArg-Gly-Asp-Ser-NH2인 화합물.
- 제10항에 있어서, Nα-Ac-Cyclo(S,S)Cys-Sar-Arg-Gly-Asp-Pen-NH2인 화합물.
- 제10항에 있어서, Nα-Ac-Cyclo(S,S)Cys-MeArg-Gly-Asp-Pen-NH2인 화합물.
- 약제로서 사용하기 위한 제1항 내지 제13항중 어느 한 항에 따르는 화합물.
- 제1항 내지 제13항중 어느 한 항에 따르는 화합물 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
- 제1항 내지 제13항중 어느 한 항에 따르는 화합물. 섬유소 용해제 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
- 제16항에 있어서, 섬유소 용해제가 스트렙토키나제, 유로키나제, 프로-유로키나제, tPA 또는 이들의 돌연변이체 또는 유도체인 약제학적 조성물.
- a) 보호된 아미노산을 커플링시켜 적절히 보호된 다음 일반식(Ⅳ)의 펩티드 화합물을 생성시키고; b) 보호그룹을 제거하고, 필요한 경우 수지로 부터 펩티드를 분해시키고, c) 임의로 이의 약제학적으로 허용되는 염을 생성시킴을 특징으로 하여, 제1항에서 정의한 바와 같은 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염을 제조하는 방법.X-(A)m-B-Gly-Asp-(C)n[Y] (Ⅳ)상기식에서 X,A,B,C,m 및 n은 제1항에서 정의한 바와 같고, [Y]는 클로로메틸, 벤즈하이드릴아민 또는 메틸벤즈하이드릴아민 수지 또는 제1항에서 정의한 Y이다.
- a) ⅰ) 임의로 보호된 일반식(Ⅴ)의 펩티드 화합물을 폐환시키고, ⅱ) 보호그룹을 제거하고, 필요한 경우 수지로부터 펩티드를 분해시키고, ⅲ) 이의 약제학적으로 허용되는 염을 임의로 형성시키거나; b) ⅰ) 임의로 보호된 일반식(Ⅴ')의 화합물을 산화적 폐환 반응시키고, ⅱ) 보호그룹을 제거하고, 필요한 경우 수지로부터 펩티드를 분해시키고, ⅲ) 이의 약제학적으로 허용되는 염을 임의로 형성시킴을 특징으로 하여; 제3항에서 정의한 바와 같은 일반식(Ⅱ)의 화합물 또는 이의 약제학적으로 허용되는 염을 제조하는 방법.상기식에서, X, Z1, A', B', C', Z2, Y, m및 n은 제3항에서 정의한 바와 같고, T1및 T2는 수소 또는 치환 가능한 그룹이며, [Y]는 클로로메틸, 벤즈하이드릴아민 또는 메틸벤즈하이드릴아민 수지 또는 제3항에서 정의한 Y이다.
- 다음 일반식의 화합물.X-(A)m-B-Gly-Asp-(C)n[Y']상기식에서 X, A, B, C, m 및 n은 제1항에서 정의한 바와 같고, [Y']는 클로로메틸, 벤즈하이드릴아민 또는 메틸벤즈하이드릴아민 수지이다.
- 일반식(Ⅴ)의 화합물.상기식에서, X, Z1, A', B', C', Z2, Y, m 및 n은 제3항에서 정의한 바와 같고, T1및 T2는 치환 가능한 그룹 또는 수소이며, [Y]는 클로로메틸, 벤즈하이드릴아민 또는 메틸벤즈하이드릴아민 수지 또는 제3항에서 정의한 Y이다.
- 섬유소용해 욧법용 약제로 사용하기 위한 제1항 또는 제3항에 따르는 화합물 및 섬유소용해제의 용도.
- 제22항에 있어서, 섬유소용해제가 스트렙토키나제, 유로키나제, tPA 또는 이의 돌연변이체 또는 유도체인 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19151588A | 1988-05-09 | 1988-05-09 | |
US191515 | 1988-05-09 | ||
US33530689A | 1989-04-10 | 1989-04-10 | |
US335,306 | 1989-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR900018136A true KR900018136A (ko) | 1990-12-20 |
Family
ID=26887117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890006198A KR900018136A (ko) | 1988-05-09 | 1989-05-09 | 항응집성 펩티드 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5849690A (ko) |
EP (1) | EP0341915B1 (ko) |
JP (1) | JP2755351B2 (ko) |
KR (1) | KR900018136A (ko) |
AT (1) | ATE158305T1 (ko) |
AU (1) | AU3458889A (ko) |
DE (1) | DE68928321T2 (ko) |
DK (1) | DK222989A (ko) |
FI (1) | FI892208A (ko) |
HU (1) | HU205368B (ko) |
NO (1) | NO891870L (ko) |
PT (1) | PT90512B (ko) |
ZW (1) | ZW6189A1 (ko) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3855458T2 (de) * | 1987-12-10 | 1996-12-05 | Jolla Cancer Res Found | Verfahren zur herstellung von conformationnell stabilisierten zelladhäsionspeptiden |
US5827821A (en) | 1987-12-10 | 1998-10-27 | The Burnham Institute | Conformationally stabilized cell adhesion peptides |
US5654267A (en) * | 1988-12-20 | 1997-08-05 | La Jolla Cancer Research Center | Cooperative combinations of ligands contained within a matrix |
JPH04503951A (ja) * | 1988-12-20 | 1992-07-16 | ラ ホヤ キャンサー リサーチ ファウンデーション | 創傷治癒に活性のあるポリペプチド―ポリマー複合体 |
US5318899A (en) * | 1989-06-16 | 1994-06-07 | Cor Therapeutics, Inc. | Platelet aggregation inhibitors |
US5770564A (en) * | 1989-06-16 | 1998-06-23 | Cor Therapeutics, Inc. | Platelet aggregation inhibitors |
US5851839A (en) * | 1989-06-16 | 1998-12-22 | Cor Therapeutics, Inc. | Platelet aggregation inhibitors |
US5344783A (en) * | 1989-06-16 | 1994-09-06 | Cor Therapeutics, Inc. | Platelet aggregation inhibitors |
US5384309A (en) * | 1989-07-17 | 1995-01-24 | Genentech, Inc. | Cyclized peptides and their use as platelet aggregation inhibitors |
US5061693A (en) * | 1989-07-28 | 1991-10-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5023233A (en) * | 1989-07-28 | 1991-06-11 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
EP0410537A1 (en) * | 1989-07-28 | 1991-01-30 | Merck & Co. Inc. | Fibrinogen receptor antagonists |
US5338723A (en) * | 1989-10-13 | 1994-08-16 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
NZ235564A (en) * | 1989-10-13 | 1993-10-26 | Merck & Co Inc | Fibrinogen receptor antagonist and pharmaceutical compositions |
US5643872A (en) * | 1989-10-23 | 1997-07-01 | Smithkline Beecham Corporation | Cyclic anti-aggregatory peptides |
AU6470590A (en) | 1989-10-23 | 1991-04-26 | Smithkline Beecham Corporation | Cyclic anti-aggregatory peptides |
WO1991011458A1 (en) * | 1990-02-02 | 1991-08-08 | Genentech, Inc. | CYCLIC PEPTIDES CONTAINING Arg-Gly-Asp FLANKED BY PROLINE |
DE4009506A1 (de) * | 1990-03-24 | 1991-09-26 | Hoechst Ag | Hydantoinderivate |
US5648330A (en) * | 1990-04-06 | 1997-07-15 | La Jolla Cancer Research Foundation | Method and composition for treating vascular graft occlusion |
DE69126871T2 (de) * | 1990-04-06 | 1998-03-12 | Jolla Cancer Res Found | Verfahren und verbindung zur behandlung von thrombose |
US6521594B1 (en) | 1990-04-06 | 2003-02-18 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
US5672585A (en) * | 1990-04-06 | 1997-09-30 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
US5612311A (en) * | 1990-04-06 | 1997-03-18 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
US5780303A (en) * | 1990-04-06 | 1998-07-14 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
US5192746A (en) * | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
US5721210A (en) * | 1990-07-09 | 1998-02-24 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
JPH06502407A (ja) * | 1990-11-02 | 1994-03-17 | ジェネンテク,インコーポレイテッド | 血小板凝集阻害剤 |
EP0570507A4 (en) * | 1991-02-05 | 1994-09-21 | Smithkline Beecham Corp | Anti-aggregatory peptides containing an aromatic ester or amide |
DE69226077T2 (de) * | 1991-04-05 | 1998-12-03 | Genentech Inc | PLAETTCHENAGGREGATIONSINHIBITOREN MIT HOHER SPEZIFIZITAET ZUM GP IIbIIIa |
AU2296792A (en) * | 1991-06-28 | 1993-01-25 | Corvas International, Inc. | Novel inhibitors of platelet aggregation |
US5939412A (en) * | 1992-06-26 | 1999-08-17 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
AU666318B2 (en) * | 1991-06-28 | 1996-02-08 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
US5635477A (en) * | 1991-09-30 | 1997-06-03 | The Dupont Merck Pharmaceutical Company | Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA |
IL103252A (en) | 1991-09-30 | 1997-03-18 | Du Pont Merck Pharma | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5565449A (en) * | 1991-10-18 | 1996-10-15 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor |
US5250679A (en) * | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
US5227490A (en) * | 1992-02-21 | 1993-07-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
FR2692899B1 (fr) * | 1992-06-30 | 1994-08-19 | Adir | Nouveaux dérivés peptidiques actifs dans les processus d'adhésion cellulaire, leur procédé de préparation et les compositions pharmaceutiques qui les renferment. |
US5338725A (en) * | 1992-06-30 | 1994-08-16 | The Research Foundation Of The State University Of New York | Anti-aggregatory agents for platelets |
FR2693107B1 (fr) * | 1992-07-01 | 1994-09-23 | Chauvin Laboratoire | Moyens pour la prévention de la cataracte secondaire. |
AU5594294A (en) * | 1992-11-18 | 1994-06-08 | Du Pont Merck Pharmaceutical Company, The | Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein iib/iiia |
US5879657A (en) * | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
US5440016A (en) * | 1993-06-18 | 1995-08-08 | Torrey Pines Institute For Molecular Studies | Peptides of the formula (KFmoc) ZZZ and their uses |
ATE195949T1 (de) * | 1993-06-18 | 2000-09-15 | Jolla Cancer Res Found | Verfahren und zusammensetzungen zur behandlung der thrombose |
MA23420A1 (fr) * | 1994-01-07 | 1995-10-01 | Smithkline Beecham Corp | Antagonistes bicycliques de fibrinogene. |
US6458784B1 (en) | 1994-06-29 | 2002-10-01 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
AU2958195A (en) * | 1994-06-29 | 1996-01-25 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin |
GB9524630D0 (en) * | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
US5977101A (en) * | 1995-06-29 | 1999-11-02 | Smithkline Beecham Corporation | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity |
EP0842195A1 (en) * | 1995-07-06 | 1998-05-20 | Zeneca Limited | Peptide inhibitors of fibronectine |
GB9613112D0 (en) | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
AP1224A (en) | 1998-03-19 | 2003-11-14 | Bristol Myers Squibb Co | Biphasic controlled release delivery system for high solubility pharmaceuticals and method. |
WO1999052493A2 (en) * | 1998-04-16 | 1999-10-21 | Texas Biotechnology Corporation | Compounds that inhibit the binding of integrins to their receptors |
US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
US6723711B2 (en) | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
WO2007082890A1 (en) * | 2006-01-17 | 2007-07-26 | N.V. Organon | SELECTIVE ENZYMATIC HYDROLYSIS OF C-TERMINAL tert-BUTYL ESTERS OF PEPTIDES |
MY161846A (en) | 2010-07-09 | 2017-05-15 | James Trinca Green | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin |
US10875875B2 (en) | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
US20210130393A1 (en) * | 2018-06-15 | 2021-05-06 | Yokogawa Electric Corporation | Method for producing amide |
EP3808759A4 (en) * | 2018-06-15 | 2021-08-11 | Yokogawa Electric Corporation | METHOD FOR PRODUCING AMIDE |
US20220055984A1 (en) * | 2018-12-25 | 2022-02-24 | Tokyo Institute Of Technology | Method for producing amide |
EP4000597A1 (en) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4397842A (en) * | 1980-03-13 | 1983-08-09 | Ortho Pharmaceutical Corporation | Peptides having thymopoietin-like activity |
US4544500A (en) * | 1982-04-14 | 1985-10-01 | Scripps Clinic And Research Foundation | Synthetic foot and mouth disease antigen |
US4661111A (en) * | 1982-08-04 | 1987-04-28 | La Jolla Cancer Research Foundation | Polypeptide |
US4578079A (en) * | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
DE3382031D1 (en) * | 1982-08-04 | 1991-01-10 | Jolla Cancer Res Found | Polypeptide. |
US4517686A (en) * | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US4589881A (en) * | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4614517A (en) * | 1982-08-04 | 1986-09-30 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4732971A (en) * | 1985-06-03 | 1988-03-22 | Eli Lilly And Company | Synthetic vaccines for foot and mouth disease |
US4683291A (en) * | 1985-10-28 | 1987-07-28 | Scripps Clinic And Research Foundation | Platelet binding inhibitors |
NZ221977A (en) * | 1986-10-09 | 1991-03-26 | Smithkline Beckman Corp | Thrombolytic composition comprising a plasminogen activator (tpa, uk or sk) and a thromboxane synthase inhibitor; kits thereof and process for preparation thereof |
US5352664A (en) * | 1986-10-31 | 1994-10-04 | Board Of Regents, The University Of Texas System | Thrombin derived polypeptides; compositions and methods for use |
DE3781263T2 (de) * | 1986-12-15 | 1993-04-08 | Inst Nat Sante Rech Med | Peptid-derivate und deren verwendung in der therapie. |
US4857508A (en) * | 1987-12-03 | 1989-08-15 | Monsanto Company | Novel platelet-aggregation inhibitor peptide derivatives |
DE3855458T2 (de) * | 1987-12-10 | 1996-12-05 | Jolla Cancer Res Found | Verfahren zur herstellung von conformationnell stabilisierten zelladhäsionspeptiden |
WO1989007609A1 (en) * | 1988-02-22 | 1989-08-24 | The Upjohn Company | Homoarginine-based peptides as platelet aggregation inhibitors |
-
1989
- 1989-05-03 ZW ZW61/89A patent/ZW6189A1/xx unknown
- 1989-05-05 DK DK222989A patent/DK222989A/da not_active Application Discontinuation
- 1989-05-05 EP EP89304541A patent/EP0341915B1/en not_active Expired - Lifetime
- 1989-05-05 AT AT89304541T patent/ATE158305T1/de not_active IP Right Cessation
- 1989-05-05 DE DE68928321T patent/DE68928321T2/de not_active Expired - Fee Related
- 1989-05-08 FI FI892208A patent/FI892208A/fi not_active Application Discontinuation
- 1989-05-08 HU HU892203A patent/HU205368B/hu not_active IP Right Cessation
- 1989-05-08 NO NO89891870A patent/NO891870L/no unknown
- 1989-05-09 KR KR1019890006198A patent/KR900018136A/ko not_active Application Discontinuation
- 1989-05-09 AU AU34588/89A patent/AU3458889A/en not_active Abandoned
- 1989-05-09 JP JP1115915A patent/JP2755351B2/ja not_active Expired - Lifetime
- 1989-05-09 PT PT90512A patent/PT90512B/pt not_active IP Right Cessation
-
1992
- 1992-07-22 US US07/918,487 patent/US5849690A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NO891870L (no) | 1989-11-10 |
JP2755351B2 (ja) | 1998-05-20 |
US5849690A (en) | 1998-12-15 |
JPH0262892A (ja) | 1990-03-02 |
DE68928321T2 (de) | 1998-04-23 |
EP0341915B1 (en) | 1997-09-17 |
AU3458889A (en) | 1989-11-09 |
EP0341915A2 (en) | 1989-11-15 |
PT90512B (pt) | 1994-10-31 |
HUT49891A (en) | 1989-11-28 |
ZW6189A1 (en) | 1990-05-09 |
ATE158305T1 (de) | 1997-10-15 |
DK222989D0 (da) | 1989-05-05 |
EP0341915A3 (en) | 1990-12-12 |
PT90512A (pt) | 1989-11-30 |
FI892208A (fi) | 1989-11-10 |
DK222989A (da) | 1989-11-10 |
DE68928321D1 (de) | 1997-10-23 |
FI892208A0 (fi) | 1989-05-08 |
NO891870D0 (no) | 1989-05-08 |
HU205368B (en) | 1992-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900018136A (ko) | 항응집성 펩티드 | |
KR910007964A (ko) | 사이클릭 항-응집성 팹티드 | |
KR0139632B1 (ko) | 브라디키닌 길항 작용을 갖는 펩티드 | |
TW343198B (en) | Cyclopeptides useful as adhesion inhibitors, process for the preparation thereof, and pharmaceutical composition containing them | |
KR910006324A (ko) | 펩티다아제 및 아이소머라제 억제제 | |
IE41510B1 (en) | Peptides having lh-rh/fsh-rh activity and proces for their manufacture | |
KR0173976B1 (ko) | 브라디키닌에 대하여 길항작용을 하는 펩타이드 | |
KR850001230A (ko) | 옥타펩티드 바조프레신 길항물질의 제조방법 | |
CA2121147C (en) | Synthetic lung surfactant having antioxidant properties | |
KR880000468A (ko) | 아미노산 유도체의 제조방법 | |
KR900001719A (ko) | 지질 및 폴리펩티드로 되는 합성 폐 계면활성제의 제조 방법 | |
KR850006941A (ko) | 데스-프로린 바조프레신 길항제의 제조방법 | |
KR100273825B1 (ko) | N 말단 변형된 펩타이드, 이의 제조방법 및 이를 함유하는 약제학적 조성물 | |
JP2552402B2 (ja) | ブラジキニン拮抗作用を有するペプチド | |
NZ209207A (en) | Cyclic hexa- and hepta-peptide vasopressin antagonists; pharmaceutical compositions | |
JP3532920B2 (ja) | 三機能性の抗血栓及び抗血小板ペプチド類 | |
KR920018074A (ko) | 사이클릭 항-응집성 펩티드 | |
LT3872B (en) | Novel peptides and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |